LYLingling Yi

Lingling Yi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lingling Yi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Dian Chen

    Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    2 shared publications
  • Yuchen Feng

    Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    2 shared publications
  • Chenli Chang

    Division of Respiratory and Critical Care Medicine Department of Internal Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China

    1 shared publication
  • Guohua Zhen

    Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    1 shared publication
  • Jianping Zhao

    Division of Respiratory and Critical Care Medicine Department of Internal Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China

    1 shared publication
  • Shengchong Chen

    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    1 shared publication

Latest Publications

  • Open Access

    Association between Galectin-13 Expression and Eosinophilic Airway Inflammation in Chronic Obstructive Pulmonary Disease

    by Lingling Yi, Yuchen Feng, Dian Chen, Yanling Jin, Shuchen Zhang

    Chronic obstructive pulmonary disease (COPD) and asthma are chronic inflammatory diseases of the airways. Galectin-13 has recently been forwarded as a biomarker for airway eosinophilic inflammation in asthma. However, the association between galectin-13 and COPD remains unknown. To examine the changes in galectin-13 expression in acute exacerbations of COPD (AECOPD) and the stable phase of COPD and unveil the association between galectin-13 expression and eosinophilic inflammation in COPD, we measured plasma galectin-13 expression in different phases of COPD patients (n = 60, 44 AECOPD patients, and 16 stable COPD patients) and healthy controls (n = 15). Plasma levels of galectin-13 in 60 COPD patients were further analyzed and compared to systemic inflammation, airway eosinophilic inflammation, and lung function. The plasma galectin-13 level was markedly increased in subjects with AECOPD compared to stable COPD patients and healthy controls. Plasma galectin-13 levels in COPD subjects were positively correlated with serum CRP (rs = 0.46, p = 0.0003), peripheral blood eosinophilia count (rs = 0.57, prs = 0.46, p = 0.0002). In addition, the level of galectin-13 was negatively correlated with FEV1 (rs = −0.43, p = 0.0001), FEV1 pred (%) (rs = −0.544, p1/FVC (rs = −0.46, p1 pred (%), peripheral blood eosinophilia count, and FeNO. We concluded that galectin-13 levels were increased in COPD patients, and elevated galectin-13 expressions related to airway eosinophilic inflammation. Galectin-13 may facilitate the identification of COPD endotypes and may become a potential therapeutic target.


  • Increased epithelial galectin‐13 expression associates with eosinophilic airway inflammation in asthma

    by Lingling Yi, Shuchen Zhang, Yuchen Feng, Wenliang Wu, Chenli Chang, Dian Chen, Shengchong Chen, Jianping Zhao, Guohua Zhen

    Background: Airway eosinophilic inflammation is a central feature in asthma which is mainly driven by type 2 response. The expression of galectin‐13 was up‐regulated in a parasitic infection model which is also characterized by type 2 immune response. We hypothesized that galectin‐13 may be involved in airway eosinophilic inflammation in asthma.Objective: To unveil the role of galectin‐13 in asthma airway inflammation.Methods: We measured galectin‐13 expressions in bronchial brushings, sputum, and plasma of asthma patients (n = 54) and healthy controls (n = 15), and analysed the correlations between galectin‐13 expression and airway eosinophilia. We used human bronchial epithelial cell line 16HBE to investigate the possible mechanism by which galectin‐13 participates in eosinophilic inflammation.Results: The expression of galectin‐13 was markedly increased in subjects with asthma compared to controls. Epithelial galectin‐13 mRNA levels in asthmatic subjects were strongly correlated with eosinophilic airway inflammation (the percentage of sputum eosinophils, the number of eosinophils in bronchial submucosa and FeNO) and the expression of Th2 signature genes (CLCA1, POSTN and SERPINB2). Inhaled corticosteroid (ICS) treatment reduced plasma galectin‐13 levels, and baseline plasma galectin‐13 levels reflect the response to ICS treatment. In cultured 16HBE cells, knockdown of galectin‐13 suppressed IL‐13‐stimulated MCP‐1 and eotaxin‐1 expression by inhibiting the activation of EGFR and ERK.Conclusions & Clinical Relevance: Galectin‐13 is a novel marker for airway eosinophilia in asthma, and may contribute to allergic airway eosinophilic inflammation by up‐regulating the expression of MCP‐1 and eotaxin‐1. Plasma galectin‐13 levels may be useful for predicting responses to ICS treatment.